Osteosarcoma and Malignant Fibrous Histiocytoma of Bone Treatment (PDQ®)–Health Professional Version

Go to Patient Version

Changes to This Summary (11/12/2018)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Osteosarcoma and Malignant Fibrous Histiocytoma (MFH) of Bone

Added Chung et al. as reference 55 and level of evidence 3iiD. Also revised text to state that in two additional series, pathologic fracture at diagnosis was associated with a worse overall outcome (cited Schlegel et al. as reference 58 and level of evidence 3iiA).

Added Davis et al. as reference 95.

Treatment of Recurrent Osteosarcoma and MFH of Bone

Added text to state that the Spanish Group for Research on Sarcoma reported the results of a phase II trial of patients with relapsed or refractory osteosarcoma who were treated with gemcitabine and sirolimus. Progression-free survival at 4 months was 44%; after central radiologic review of 33 assessable patients, 2 partial responses and 14 disease stabilizations (48.5%) were reported (cited Martin-Broto et al. as reference 50 and level of evidence 3iiDiv).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Treatment of Recurrent Osteosarcoma and MFH of Bone

Next section >
About This PDQ Summary